Compare Ginkgo Bioworks Holdings Inc (DNA) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while Consumer Staples Select Sector SPDR Fund trades at $83.43 (market cap $13.50B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 17.7× Ginkgo Bioworks Holdings Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Consumer Staples Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Consumer Staples Select Sector SPDR Fund for 72 Days on average.
| DNA | XLP | |
|---|---|---|
Market Cap | $763.64M | $13.50B |
Volume | 3,204,177 | 14,599,953 |
Sector | Health | — |
52-Week High | $15.83 | $90.00 |
52-Week Low | $5.48 | $75.61 |
Typical Hold Time | 7 Days | 72 Days |
Enterprise Value | $865.59M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.34, down 1.13% on the day. The technical outlook is bullish based on moving averages, while oscillators are neutral. Fundamentally, the company reported a net loss of $312.76 million on $170.16 million revenue for 2025, with a negative net income margin of -219.6%. Recent news includes a partnership with TuneLab and a $17.5 million ARPA-H subcontract.
The outlook is challenged by persistent losses and negative cash flow, though strategic partnerships offer growth potential. Analyst sentiment is divided evenly between buy, hold, and sell ratings. Key risks include execution on profitability and high cash burn. The stock presents a speculative opportunity dependent on the company's ability to monetize its technology platform.
XLP trades at $83.42, up 2.11% with a bullish technical signal supported by moving averages and oscillators. The ETF shows strong relative performance against discretionary peers, gaining 6.6% year-to-date while XLY declined over 7%. Analyst consensus is unanimously bullish with 100% buy ratings. Recent news highlights XLP's defensive characteristics amid economic uncertainty and its competitive expense ratio advantage over peer funds.
The outlook remains positive given XLP's defensive positioning in consumer staples, low 0.08% expense ratio, and strong technical momentum. However, risks include sensitivity to interest rate movements and potential consumer spending slowdown. The ETF's proximity to resistance at $84 suggests near-term consolidation may precede further upside if bullish momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
